The landscape of cardiometabolic disease management is undergoing a seismic shift driven by a blockbuster new class of drugs, GLP-1 agonists, which have profound implications for the future of care. Just for diabetes, recent data has shown that they are now the second-most prescribed medication, ahead of even insulin. However, the growth of these drugs will impact all health economy stakeholders differently, including patients, providers, payers, employers and even policymakers. Let's explore the latest trends in GLP-1 prescribing and unpack how the cardiometabolic healthcare landscape will fundamentally shift moving forward.
